These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 27515347)

  • 41. Salicylanilide carbamates: antitubercular agents active against multidrug-resistant Mycobacterium tuberculosis strains.
    Férriz JM; Vávrová K; Kunc F; Imramovský A; Stolaríková J; Vavríková E; Vinsová J
    Bioorg Med Chem; 2010 Feb; 18(3):1054-61. PubMed ID: 20060303
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
    Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
    J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis.
    Sacchettini JC; Rubin EJ; Freundlich JS
    Nat Rev Microbiol; 2008 Jan; 6(1):41-52. PubMed ID: 18079742
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Resistance to antitubercular drugs in Chile].
    Valenzuela MT; Scheel G; Ponce J; Lepe R; Velasco M; Valenzuela P
    Rev Med Chil; 1984 Jan; 112(1):76-80. PubMed ID: 6429808
    [No Abstract]   [Full Text] [Related]  

  • 45. Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.
    Cavaleri M; Manolis E
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S1-4. PubMed ID: 26224766
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Prevalence of primary drug resistance in M. tuberculosis in four administrative areas of the North-Western Federal District of the Russian Federation].
    Baranov AA; Mar'iandyshev AO; Nizovtseva NI; Oparina EN; Presnova SE; Gvozdovskaia LA; Markelov IuM; Trekin IA; Tungusova OS; Mannsoker T
    Probl Tuberk Bolezn Legk; 2006; (12):9-12. PubMed ID: 17300065
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug resistance of Mycobacterium tuberculosis in Karachi, Pakistan.
    Khan J; Islam N; Ajanee N; Jafri W
    Trop Doct; 1993 Jan; 23(1):13-4. PubMed ID: 8438507
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Incidence of resistant mutants of Mycobacterium tuberculosis (MT) strains from different areas of Rumania. Bacteriological study--epidemiological aspects].
    Anastasatu C; Băicoianu S; Teodorescu A
    Arch Roum Pathol Exp Microbiol; 1970; 29(1):212-22. PubMed ID: 4998673
    [No Abstract]   [Full Text] [Related]  

  • 49. Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs.
    Nikonenko BV; Protopopova M; Samala R; Einck L; Nacy CA
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1563-5. PubMed ID: 17242141
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The achievements of the fundamental sciences and new approaches in the chemotherapy of tuberculosis].
    Egorov AM
    Probl Tuberk; 2000; (5):11-5. PubMed ID: 11077844
    [No Abstract]   [Full Text] [Related]  

  • 51. [Sensitivity of strains, populations and clones of mycobacterium tuberculosis to tuberculostatic agents].
    Bakanova DIa; Kochemasova EN
    Probl Tuberk; 1968; 46(4):66-9. PubMed ID: 4970334
    [No Abstract]   [Full Text] [Related]  

  • 52. [Mechanism of action "in vitro" and "in vivo" of antitubercular drugs].
    Gialdroni-Grassi G
    G Ital Chemioter; 1966; 13(1):11-26. PubMed ID: 4967319
    [No Abstract]   [Full Text] [Related]  

  • 53. Novel proteasome inhibitors as potential drugs to combat tuberculosis.
    Cheng Y; Pieters J
    J Mol Cell Biol; 2010 Aug; 2(4):173-5. PubMed ID: 20123700
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mycobacterium tuberculosis cytochrome P450 enzymes: a cohort of novel TB drug targets.
    Hudson SA; McLean KJ; Munro AW; Abell C
    Biochem Soc Trans; 2012 Jun; 40(3):573-9. PubMed ID: 22616869
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Medicine. New TB drug promises shorter, simpler treatment.
    Cohen J
    Science; 2004 Dec; 306(5703):1872. PubMed ID: 15591168
    [No Abstract]   [Full Text] [Related]  

  • 56. Novel targets in M. tuberculosis: search for new drugs.
    Lamichhane G
    Trends Mol Med; 2011 Jan; 17(1):25-33. PubMed ID: 21071272
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enhancement of apoptosis of THP-1 cells infected with Mycobacterium tuberculosis by inhalable microparticles and relevance to bactericidal activity.
    Yadav AB; Misra A
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3740-2. PubMed ID: 17664326
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Course of murine tuberculosis and response to first-line therapy depends on route of infection and inoculum size.
    de Steenwinkel JE; ten Kate MT; de Knegt GJ; Verbrugh HA; van Belkum A; Hernandez-Pando R; Bakker-Woudenberg IA
    Int J Tuberc Lung Dis; 2011 Nov; 15(11):1478-84, i. PubMed ID: 22008760
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Comparative examinations of mycobacteria growth rates on cultures with 1 tuberculostatic or several combined antitubercular agents].
    Sonntag HG; Ratschko KW
    Beitr Klin Erforsch Tuberk Lungenkr; 1970; 141(4):319-27. PubMed ID: 4994471
    [No Abstract]   [Full Text] [Related]  

  • 60. [Discrepancy between drug resistance of mycobacterium tuberculosis determined in vitro and in vivo].
    Belogurova VP; Gorislavets II; Ivanitskaia NN
    Probl Tuberk; 1971; 49(6):76-80. PubMed ID: 5000746
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.